Case Details
- Citation: [2013] SGHC 266
- Court: High Court of the Republic of Singapore
- Decision Date: 29 November 2013
- Coram: Sundaresh Menon CJ; Chao Hick Tin JA; V K Rajah JA
- Case Number: Originating Summons No 799 of 2012
- Hearing Date(s): The DC inquiry was held over eight days
- Claimants / Plaintiffs: Pang Ah San
- Respondent / Defendant: Singapore Medical Council
- Counsel for Claimants: Gregory Vijayendran, Lester Chua, and Jason Gabriel Chiang (Rajah & Tann LLP)
- Counsel for Respondent: Melanie Ho, Chang Man Phing, Sim Mei Ling, and Chang Qi-Yang (WongPartnership LLP)
- Practice Areas: Medical Law; Professional Misconduct; Disciplinary Proceedings
Summary
The judgment in Pang Ah San v Singapore Medical Council stands as a definitive statement on the ethical and legal boundaries governing medical innovation in Singapore. The case arose from an appeal by Dr Pang Ah San, a general surgeon, against a finding of professional misconduct by a Disciplinary Committee (DC). The misconduct was predicated on Dr Pang’s performance of a "loop" percutaneous endoscopic gastrostomy ("loop-PEG") procedure on an 84-year-old patient. The central ethical breach concerned the offering of a medical remedy that was not generally accepted by the profession and was not conducted within the protective framework of a formal and approved clinical trial.
The High Court, comprising Sundaresh Menon CJ, Chao Hick Tin JA, and V K Rajah JA, dismissed the appeal, affirming that technical competency does not absolve a practitioner from the mandatory ethical requirements set out in the Singapore Medical Council (SMC) Ethical Code and Ethical Guidelines (ECEG). The court emphasized that the "generally accepted" standard serves as a critical safeguard against the premature or unsafe introduction of novel treatments. By performing the loop-PEG procedure—which involved the surgical insertion of a novel device—outside of a clinical trial, Dr Pang bypassed the institutional oversight necessary to protect vulnerable patients from the risks inherent in experimental medicine.
Doctrinally, the case clarifies the interpretation of Clause 4.1.4 of the ECEG, rejecting a narrow reading that would distinguish between "remedies" and "treatments" to exclude surgical procedures from ethical oversight. The court held that any invasive procedure involving a novel device or method must meet the threshold of general acceptance or be subjected to the rigours of a clinical trial. This decision reinforces the principle that the protection of patient interests is paramount, particularly in an environment of information asymmetry where patients and their families may not fully grasp the experimental nature of a recommended procedure.
The broader significance of this judgment lies in its articulation of the balance between fostering medical innovation and ensuring patient safety. While the court acknowledged the value of progress in medical science, it maintained that such progress must occur within regulated channels. The ruling serves as a stern reminder to the medical community that deviations from established practice, however well-intentioned or technically successful, must be grounded in evidence-based consensus or formal research protocols to avoid the stigma and legal consequences of professional misconduct.
Timeline of Events
- 18 April 1979: [Date referenced in regex metadata regarding historical context or practitioner background].
- 25 June 1998: [Date referenced in regex metadata regarding historical context or practitioner background].
- 11 October 2007: [Date referenced in regex metadata regarding prior events or medical history].
- 30 June 2008: Initial consultation or recommendation regarding the feeding tube procedure for the Patient.
- 7 July 2008: Dr Pang Ah San performs the loop-PEG procedure on Mdm Goh Lee Kheng at Mount Alvernia Hospital.
- 9 July 2008: The Patient is discharged from the hospital following the procedure.
- 8 August 2008: Two of the Patient’s children lodge a formal complaint with the Singapore Medical Council via a joint statutory declaration.
- 31 August 2009: [Date referenced in regex metadata regarding the progression of the complaint or investigation].
- 1 December 2010: [Date referenced in regex metadata regarding the disciplinary process].
- 12 October 2011: The Disciplinary Committee delivers its decision finding Dr Pang guilty of professional misconduct.
- 19 October 2011: [Date referenced in regex metadata regarding post-decision filings or orders].
- 23 July 2012: Dr Pang files Originating Summons No 799 of 2012 to appeal the DC's decision.
- 29 November 2013: The High Court delivers its judgment dismissing the appeal and upholding the finding of professional misconduct.
What Were the Facts of This Case?
Dr Pang Ah San was a general surgeon of 26 years’ standing at the time of the events, having operated a private practice at Mount Alvernia Medical Centre for approximately 18 years. His clinical experience was extensive, particularly in gastrostomy and laparotomy procedures, having performed approximately 50 standard percutaneous endoscopic gastrostomy (PEG) procedures. The standard PEG is a widely accepted method for providing long-term enteral nutrition to patients who cannot swallow safely.
The patient at the centre of the dispute was Mdm Goh Lee Kheng, an 84-year-old woman who had suffered a stroke and required permanent tube feeding. In mid-2008, the Patient's family sought medical advice regarding her feeding requirements. Dr Pang recommended the "loop-PEG" procedure, asserting that it was a superior alternative to the standard PEG tube. The loop-PEG involved the surgical insertion of a device that Dr Pang himself had developed or was championing. Unlike the standard PEG, the loop-PEG procedure was invasive and involved a different mechanism for securing the feeding tube within the gastric wall.
On 7 July 2008, Dr Pang carried out the loop-PEG procedure on the Patient at Mount Alvernia Hospital. He was assisted by his wife, Dr Chia Siew Cheng, who was also a medical practitioner. While the procedure was completed and the Patient was discharged on 9 July 2008, her health subsequently declined, and she passed away 20 days after the surgery. Following her death, the Patient's son, Mr Tan Kwang Chuan, and another sibling filed a complaint with the Singapore Medical Council (SMC) on 8 August 2008.
The SMC's investigation led to a formal inquiry before a Disciplinary Committee. The primary allegation was that Dr Pang had committed professional misconduct under Section 45(1)(d) of the Medical Registration Act (Cap 174, 2004 Rev Ed). Specifically, the charge alleged a breach of Clause 4.1.4 of the SMC Ethical Code and Ethical Guidelines (ECEG). This clause mandates that a doctor shall only offer "remedies" that are "generally accepted by the profession" unless they are provided within the context of a "formal and approved clinical trial."
During the eight-day DC inquiry, the prosecution relied heavily on the expert testimony of Professor Ti Thiow Kong ("Prof Ti"). Prof Ti testified that the loop-PEG procedure was not a generally accepted practice within the medical community in Singapore or internationally. He highlighted that the device and the specific surgical technique employed by Dr Pang lacked the necessary peer-reviewed evidence and clinical validation to be considered a standard treatment. The DC also heard evidence from the Patient's family regarding the information provided to them by Dr Pang prior to the surgery. The family contended that they were not adequately informed that the loop-PEG was an experimental or novel procedure, nor were they told that the Patient would be among the first few individuals globally to undergo this specific intervention.
Dr Pang's defence rested on the argument that the loop-PEG was a modification of an existing procedure and that his technical competency ensured the safety of the Patient. He argued that the ECEG should not be interpreted so strictly as to stifle innovation that could benefit patients. However, the DC found that the loop-PEG procedure was indeed novel and not generally accepted. Furthermore, it was undisputed that Dr Pang had not sought approval from an Institutional Review Board (IRB) nor conducted the procedure as part of a formal clinical trial. Consequently, the DC found Dr Pang guilty of professional misconduct. Dr Chia Siew Cheng, who assisted in the procedure, was also charged but was ultimately acquitted by the DC. Dr Pang subsequently appealed the conviction to the High Court.
What Were the Key Legal Issues?
The appeal before the High Court necessitated a rigorous examination of the intersection between medical ethics, statutory regulation, and the practicalities of clinical innovation. The overarching issue was whether the DC erred in finding Dr Pang guilty of professional misconduct under Section 45(1)(d) of the Medical Registration Act.
To resolve this, the court addressed several sub-issues:
- The Interpretation of "Remedies" vs. "Treatments" (Issue 1): Whether the DC erred in law by convicting Dr Pang based on the surgical "treatment" provided, when the particulars of the charge referenced Clause 4.1.4 of the ECEG, which uses the term "remedies." Dr Pang argued that "remedies" referred only to medicinal products and not to surgical procedures.
- The "Generally Accepted" Standard: What constitutes a remedy that is "generally accepted by the profession"? This required the court to define the threshold of peer consensus and evidence-based practice required to move a treatment from the realm of "experimental" to "standard."
- The Clinical Trial Requirement: Whether the loop-PEG procedure, being novel, was mandatory to be performed only within a "formal and approved clinical trial" as defined by the ECEG and relevant statutes like the Medicines Act and the Health Products Act.
- The Role of Informed Consent in Innovation: To what extent does a practitioner's failure to disclose the novel or experimental nature of a procedure contribute to a finding of professional misconduct, even if the patient or their family provided "consent" to the surgery?
- The Regulatory Framework for Innovation: How the law should balance the need for medical progress with the necessity of post hoc regulation via disciplinary proceedings to ensure public confidence in the medical profession.
How Did the Court Analyse the Issues?
The High Court’s analysis began with a deep dive into the statutory and ethical framework governing medical practice in Singapore. The court affirmed that professional misconduct under Section 45(1)(d) of the Medical Registration Act is a serious finding that reflects a departure from the standards of conduct expected of a medical practitioner. The court relied on the principles established in Low Cze Hong v Singapore Medical Council [2008] 3 SLR(R) 612, noting that misconduct involves a "failure to do that which a medical practitioner of reasonable competence would do" or "doing that which a medical practitioner of reasonable competence would not do."
The Interpretation of Clause 4.1.4 and "Remedies"
Dr Pang’s primary legal challenge (Issue 1) was a linguistic one. He contended that Clause 4.1.4 of the ECEG, which prohibits offering "remedies" that are not generally accepted, was intended to apply only to medicinal substances and not to surgical procedures. The court rejected this narrow interpretation. It held that the term "remedies" must be understood in the context of the ECEG’s overarching purpose: the protection of patients. The court observed that it would be "illogical and counter-intuitive" to suggest that the SMC intended to regulate novel drugs while leaving novel, invasive surgical procedures entirely unregulated by the same ethical standard.
The court clarified the position by referring to Low Chai Ling v Singapore Medical Council [2013] 1 SLR 83, where it was noted that the DC rightly rejected a narrow reading of the ECEG. The court held that "remedies" encompasses any form of medical intervention, including surgical treatments. Therefore, the loop-PEG procedure fell squarely within the ambit of Clause 4.1.4.
The "Generally Accepted" Standard
The court then addressed what it means for a treatment to be "generally accepted by the profession." It adopted the reasoning from Gobinathan Devathasan v Singapore Medical Council [2010] 2 SLR 926, which stated:
"whenever appropriate, patients should be treated with time tested methods where the benefits and risks have been well researched and documented. The purpose of requiring doctors to conform to generally accepted practices is to ensure that 'patients suffer no harm'." (at [45])
In applying this to Dr Pang’s case, the court looked at the evidence regarding the loop-PEG. The procedure was "invasive" and involved the "surgical insertion of a device" (at [29]). The expert evidence from Prof Ti was pivotal. Prof Ti established that the loop-PEG was not part of the standard curriculum, was not featured in standard surgical textbooks as an accepted practice, and lacked a body of peer-reviewed literature supporting its safety and efficacy compared to the standard PEG. The court found that a single practitioner's belief in the superiority of their own invention does not constitute "general acceptance." Acceptance requires a consensus among peers, typically built through rigorous testing and publication.
The Clinical Trial Mandate
A critical part of the court's reasoning concerned the "clinical trial" exception in Clause 4.1.4. The clause provides a binary choice for practitioners: either use a generally accepted remedy or, if the remedy is not generally accepted, use it only within a formal and approved clinical trial. The court noted that the loop-PEG procedure did not fall under the specific clinical trial regulatory regimes of the Medicines Act (Cap 176, 1985 Rev Ed) or the Health Products Act (Cap 122D, 2008 Rev Ed) because it was a surgical procedure rather than a drug or a regulated health product (at [22]).
However, the court held that this did not exempt Dr Pang from the ethical requirement of a clinical trial. The absence of a specific statutory regime for surgical trials meant that the practitioner had an even greater responsibility to seek institutional oversight, such as through a hospital's Ethics Committee or an IRB. The court emphasized that therapy is "patient-centric" and that the protection of the patient undergoing "treatment under therapy instead of research is ensured largely by post hoc regulation" (at [65]). By bypassing these safeguards, Dr Pang deprived the Patient of the protections that a formal trial protocol would have provided, such as independent monitoring and a structured assessment of risks.
Informed Consent and Information Asymmetry
The court also touched upon the issue of informed consent, though it was not the sole basis for the misconduct finding. It noted that the Patient was 84 years old and vulnerable. In such cases, the "information asymmetry" between the doctor and the patient is at its peak. The court referred to Khoo James v Gunapathy d/o Muniandy [2002] 1 SLR(R) 1024 to underscore the importance of the doctor's duty to provide sufficient information. In the context of an experimental procedure, this duty is heightened. Dr Pang’s failure to explicitly inform the family that the loop-PEG was novel and not generally accepted was a significant factor in the ethical breach.
The Rejection of Technical Competency as a Defence
Dr Pang argued that because he was a competent surgeon and the procedure was technically successful (in that the tube was inserted), he should not be found guilty of misconduct. The court rejected this, stating that professional misconduct is not limited to technical incompetence. It also encompasses ethical failures. A doctor who performs an unproven, experimental procedure on a patient without following the required ethical protocols is guilty of misconduct regardless of the technical outcome of the surgery. The court held that the ECEG exists to prevent doctors from using patients as "test subjects" without the necessary institutional checks and balances.
What Was the Outcome?
The High Court dismissed Dr Pang Ah San’s appeal in its entirety. The court found no reason to disturb the findings of the Disciplinary Committee, concluding that the evidence overwhelmingly supported the charge of professional misconduct. The court affirmed that the loop-PEG procedure was not generally accepted by the medical profession and that Dr Pang’s failure to conduct the procedure within the framework of a formal and approved clinical trial constituted a clear breach of Clause 4.1.4 of the ECEG.
The operative conclusion of the court was recorded as follows:
"we dismissed Originating Summons No 799 of 2012, and ordered that the costs incurred be borne by the Appellant." (at [127])
In terms of costs, the court ordered that Dr Pang bear the costs of the Respondent, the Singapore Medical Council. While the specific quantum of the fine or the duration of any suspension imposed by the DC was not the primary focus of the High Court’s grounds of decision, the dismissal of the appeal meant that the DC’s original sanctions remained in force. The court’s decision effectively finalized the disciplinary process, confirming that Dr Pang’s actions fell below the standards expected of the medical profession in Singapore.
The outcome also had significant implications for the "loop-PEG" procedure itself. By affirming that it was not a generally accepted treatment, the court effectively prohibited its use in general clinical practice in Singapore unless and until it underwent the rigorous process of a formal clinical trial and achieved peer acceptance. The judgment served as a definitive stop to the ad hoc use of this specific innovative technique outside of regulated research environments.
Why Does This Case Matter?
Pang Ah San v Singapore Medical Council is a landmark decision in Singapore’s medical jurisprudence, particularly regarding the regulation of medical innovation. It establishes a clear "bright line" for practitioners: innovation must not come at the expense of established ethical safeguards. The case is a primary authority for the interpretation of the SMC Ethical Code and Ethical Guidelines, specifically Clause 4.1.4, and its application to surgical procedures.
First, the case clarifies that the term "remedies" in the ECEG is to be interpreted broadly. This prevents a regulatory vacuum where surgical innovations could be introduced without the same level of scrutiny as new pharmaceuticals. For practitioners, this means that any novel intervention—whether it involves a drug, a device, or a new surgical technique—must be measured against the "generally accepted" standard. This ensures a consistent ethical standard across all branches of medicine.
Second, the judgment reinforces the necessity of the clinical trial framework. The court’s analysis highlights that clinical trials are not merely administrative hurdles but are essential for patient safety. They provide a structured environment where risks are monitored by independent bodies (like IRBs). By insisting that non-generally accepted treatments be confined to such trials, the court protects vulnerable patients from being subjected to unproven and potentially harmful interventions under the guise of "innovative therapy."
Third, the case addresses the "vulnerability" of patients in the face of medical innovation. The court’s recognition of information asymmetry is a crucial reminder to doctors that "consent" is only valid if it is truly informed. In the context of experimental medicine, the burden on the doctor to disclose the lack of general acceptance and the potential risks is significantly higher. This has direct implications for how doctors should conduct pre-operative consultations for any procedure that deviates from standard practice.
Fourth, the decision places the responsibility for medical progress on the collective profession rather than the individual practitioner. By requiring "general acceptance," the law ensures that new treatments are vetted by the scientific community through peer review and documented research. This prevents "maverick" doctors from imposing their own unverified methods on patients. It balances the individual doctor’s desire to innovate with the profession’s collective duty to maintain high standards of safety and evidence-based care.
Finally, the case underscores the role of the High Court in supervising professional disciplinary bodies. While the court will respect the expertise of the DC, it will not hesitate to intervene to ensure that ethical guidelines are interpreted in a way that fulfills their protective purpose. This judgment provides a clear roadmap for future disciplinary inquiries involving innovative treatments, ensuring that the focus remains on whether the practitioner adhered to the mandatory ethical pathways for introducing new medical remedies.
Practice Pointers
- Verify "General Acceptance": Before introducing a new procedure or device, practitioners must objectively assess whether it is "generally accepted" by the profession. This involves checking standard textbooks, peer-reviewed journals, and clinical guidelines. A personal belief in a method's superiority is insufficient.
- Mandatory Clinical Trial Framework: If a treatment is not generally accepted, it must be conducted within a formal and approved clinical trial. Practitioners should seek approval from an Institutional Review Board (IRB) or a hospital Ethics Committee, even if the procedure does not fall under the strict remit of the Medicines Act.
- Heightened Disclosure Duties: When proposing a novel or experimental treatment, doctors must explicitly inform the patient (and their family) that the treatment is not standard, the reasons for its novelty, and the lack of long-term data. The fact that a patient is among the first to undergo a procedure is a material fact that must be disclosed.
- Avoid "Innovative Therapy" as a Shield: Technical success or the absence of immediate harm does not excuse a failure to follow ethical protocols. Professional misconduct can be found based on the process of offering the treatment, regardless of the surgical outcome.
- Document Institutional Oversight: Practitioners should maintain clear records of any consultations with peers or ethics committees regarding the use of novel techniques. Documentation of the evidential basis for the procedure is critical in defending against potential disciplinary charges.
- Understand the Scope of "Remedies": Do not assume that ethical guidelines using the word "remedies" apply only to drugs. The courts interpret such terms broadly to include all forms of medical and surgical intervention.
- Vulnerability Assessment: Be particularly cautious when recommending novel procedures to elderly or stroke-impaired patients. The court views these patients as highly vulnerable, and any perceived exploitation of information asymmetry will be viewed severely in disciplinary proceedings.
Subsequent Treatment
The decision in Pang Ah San v Singapore Medical Council has been consistently cited in subsequent Singaporean cases involving medical disciplinary proceedings and the interpretation of the ECEG. It is the leading authority for the proposition that Clause 4.1.4 of the ECEG creates a mandatory binary choice for doctors: use generally accepted methods or use a formal clinical trial. Later cases have affirmed the court's rejection of a narrow interpretation of "remedies," ensuring that surgical and aesthetic procedures remain subject to the same ethical rigour as pharmaceutical treatments. The ratio regarding the "generally accepted" standard continues to guide Disciplinary Tribunals in assessing whether a practitioner's departure from standard care constitutes professional misconduct.
Legislation Referenced
- Medical Registration Act (Cap 174, 2004 Rev Ed), Section 45(1)(d), s 46(8)
- Medicines Act (Cap 176, 1985 Rev Ed)
- Health Products Act (Cap 122D, 2008 Rev Ed)
- Private Hospitals and Medical Clinics Act (Cap 248)
Cases Cited
- Considered: Gobinathan Devathasan v Singapore Medical Council [2010] 2 SLR 926
- Referred to: Low Chai Ling v Singapore Medical Council [2013] 1 SLR 83
- Referred to: Low Cze Hong v Singapore Medical Council [2008] 3 SLR(R) 612
- Referred to: Khoo James v Gunapathy d/o Muniandy and another appeal [2002] 1 SLR(R) 1024